Aclarion (ACON) Stock Price, News & Analysis

Company Overview

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

Key Stats

• Today's Range: $7.30 to $7.60
• 50-Day Range: $6.80 to $7.84
• 52-Week Range: $6.20 to $3,499.51
• Volume: 6,310 shs
• Average Volume: 93,966 shs
• Market Capitalization: $4.23 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11,758.50
• Consensus Rating: Hold

Aclarion Stock Analysis - MarketRank™

Aclarion scored higher than 32% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Aclarion has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Aclarion has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Aclarion are expected to grow in the coming year, from ($263.33) to ($216.67) per share.

Price to Book Value per Share Ratio

Aclarion has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.06% of the float of Aclarion has been sold short.

Short Interest Ratio / Days to Cover

Aclarion has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aclarion has recently increased by 11.32%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aclarion does not currently pay a dividend.

Dividend Growth

Aclarion does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.06% of the float of Aclarion has been sold short.

Short Interest Ratio / Days to Cover

Aclarion has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aclarion has recently increased by 11.32%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Sentiment

Aclarion has a news sentiment score of -3.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aclarion insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.77% of the stock of Aclarion is held by insiders.

Percentage Held by Institutions

Only 7.52% of the stock of Aclarion is held by institutions.

ACON Stock Analysis - Frequently Asked Questions

How have ACON shares performed this year?

Aclarion's stock was trading at $1,302.48 at the beginning of the year. Since then, ACON stock has decreased by 99.4% and is now trading at $7.38.

How were Aclarion's earnings last quarter?

Aclarion, Inc. (NASDAQ:ACON) announced its quarterly earnings results on Thursday, August, 14th. The company reported ($2.75) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.26) by $0.49. The company earned $0.02 million during the quarter, compared to analysts' expectations of $0.03 million. Aclarion had a negative trailing twelve-month return on equity of 83.63% and a negative net margin of 11,238.59%.

When did Aclarion's stock split?

Aclarion shares reverse split before market open on Friday, March 28th 2025.The 1-27 reverse split was announced on Wednesday, March 26th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

When did Aclarion IPO?

Aclarion (ACON) raised $12 million in an initial public offering (IPO) on Friday, April 22nd 2022. The company issued 2,165,000 shares at $4.50-$6.50 per share.

How do I buy shares of Aclarion?

Shares of ACON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Aclarion own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aclarion investors own include Broadcom (AVGO), Meta Platforms (META), Norwegian Cruise Line (NCLH), Audioeye (AEYE), Advanced Micro Devices (AMD), ASML (ASML) and AvidXchange (AVDX).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 8/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:ACON
• CIK: 1635077
• Web: www.aclarion.com
• Phone: 833-275-2266
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Aclarion: $11,758.50
• High Price Target: $11,758.50
• Low Price Target: $11,758.50
• Potential Upside/Downside: +159,229.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.99 million
• Net Margins: -11,238.59%
• Pretax Margin: -11,238.59%
• Return on Equity: -83.63%
• Return on Assets: -76.55%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 23.83
• Quick Ratio: 21.68

Sales & Book Value

• Annual Sales: $50 thousand
• Price / Sales: 85.61
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $24.37 per share
• Price / Book: 0.30

Miscellaneous

• Outstanding Shares: 580,000
• Free Float: 578,000
• Market Cap: $4.28 million
• Optionable: Not Optionable
• Beta: 1.34